Review
Radiology, Nuclear Medicine & Medical Imaging
Benjamin Koa, Austin J. Borja, Mahmoud Aly, Sayuri Padmanabhan, Joseph Tran, Vincent Zhang, Chaitanya Rojulpote, Sheila K. Pierson, Mark-Avery Tamakloe, Johnson S. Khor, Thomas J. Werner, David C. Fajgenbaum, Abass Alavi, Mona-Elisabeth Revheim
Summary: Castleman disease is a rare hematologic condition involving lymphadenopathy and clinical abnormalities, classified into UCD and MCD; MCD is further divided based on etiological driver; FDG-PET/CT plays an important role in differential diagnosis and monitoring treatment responses.
INSIGHTS INTO IMAGING
(2021)
Article
Multidisciplinary Sciences
Wen-yu Yin, Jiao Yuan, Zhi-min Zhang, Cheng Mei, Wei Xu, Yong-xiang Tang, Fang Peng, Ning Li
Summary: Stressed red blood cells showed differences in various indicators compared to untreated red blood cells, being more prone to phagocytosis by macrophages and mainly trapped in the spleen as shown by F-18-FDG PET/CT imaging, while the untreated red blood cells continued to circulate in the system.
SCIENTIFIC REPORTS
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Moath Said Alfawara, Ahmed Ibrahim Ahmed, Jean Michel Saad, Yushui Han, Fares Alahdab, Mahmoud Al Rifai, Mahwash Kassi, Talal Alnabelsi, William A. Zoghbi, Mouaz H. Al-Mallah
Summary: This study evaluated the use of serum beta-hydroxybutyrate (BHB) to identify adequate suppression of the left ventricle (LV) in patients undergoing cardiac inflammatory/infectious studies. The results showed that serum BHB level can be used to determine sufficient LV suppression.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Rheumatology
Kaitlin A. Quinn, Hugh Alessi, Cristina Ponte, Emily Rose, Mark A. Ahlman, Christopher Redmond, Yiming Luo, Ertugrul Cagri Bolek, Carol A. Langford, Peter A. Merkel, Peter C. Grayson
Summary: This study assessed the importance of incorporating FDG-PET data into eligibility criteria for clinical trials in TAK. The results showed that FDG-PET data can influence physicians' decisions about enrollment in trials and improve the accuracy and consistency of clinical assessment. Therefore, future trials in TAK should consider including FDG-PET data in eligibility criteria.
Article
Radiology, Nuclear Medicine & Medical Imaging
Hai-Jeon Yoon, Kyoungjune Pak
Summary: This study aimed to assess the impact of F-18-FDG PET on the management of lung cancer, revealing its significant role in detecting lung cancer recurrence/metastasis, especially in cases involving equivocal or suspicious recurrence/metastasis on conventional imaging.
CLINICAL NUCLEAR MEDICINE
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Yun Hye Song, Jung Won Moon, Yoo Na Kim, Ji Young Woo, Hye Joo Son, Suk Hyun Lee
Summary: This study aimed to investigate the reduction of [F-18]FDG uptake in dependent lungs by performing [F-18]FDG PET/CT in the prone position. The results showed that dependent lungs had significantly higher SUVmean and HU compared to nondependent lungs on both supine and prone position PET/CT. The study concluded that prone position PET/CT can effectively reduce gravity-dependent opacity-related [F-18]FDG uptake.
EUROPEAN RADIOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Virginia Liberini, Michael Messerli, Lars Husmann, Ken Kudura, Hannes Grunig, Alexander Maurer, Stephan Skawran, Erika Orita, Daniele A. Pizzuto, Desiree Deandreis, Reinhard Dummer, Joanna Mangana, Daniela Mihic-Probst, Niels Rupp, Martin W. Huellner
Summary: BSREM detects significantly more ITM than OSEM, with higher SUVmax, higher TBR, and less blurring. BSREM is particularly helpful in small and less avid lesions, which are more often missed with OSEM.
EUROPEAN RADIOLOGY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Kailin Qiao, Xueting Qin, Shuai Fu, Jiazhong Ren, Jing Jia, Xinying Hu, Yuanyuan Tao, Shuanghu Yuan, Yuchun Wei
Summary: The uptake of [F-18]AlF-NOTA-FAPI-04 and [F-18]FDG imaging tracers varies in malignant and inflammatory lung lesions, with lower uptake observed in inflammatory lesions. This difference in uptake can be valuable for distinguishing between malignancy and various inflammatory findings.
EUROPEAN RADIOLOGY
(2023)
Article
Clinical Neurology
Kai Wang, Xiaobin Zhao, Leilei Yuan, Qian Chen, Qun Wang, Lin Ai
Summary: An asymmetric F-18-FDG metabolic pattern exists in patients with anti-LGI1 encephalitis, and varied regional metabolic differences were revealed bilaterally in specific cerebral areas.
FRONTIERS IN NEUROLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Joao Borges-Rosa, Manuel Oliveira-Santos, Rodolfo Silva, Andreia Gomes, Jose de Almeida, Gracinda Costa, Lino Goncalves, Maria Joao Ferreira
Summary: In patients with biopsy-proven sarcoidosis, cardiac involvement detected by [18F]FDG-PET or CMR is associated with a higher risk of cardiovascular events, regardless of symptoms. Patients with probable CS had a higher prevalence of heart failure, atrial fibrillation, coronary disease, and valvular disease compared to those without cardiac involvement. Probable CS patients had significantly higher rates of heart failure hospitalizations, uncontrolled arrhythmias, and pacemaker implantation during follow-up, with a trend towards increased all-cause mortality.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2022)
Article
Clinical Neurology
Jeong-Min Kim, Eun Seong Lee, Kwang-Yeol Park, Ju Won Seok
Summary: Stroke patients with carotid atherosclerosis had decreased FDG uptake in the lumbar vertebrae compared to control subjects. Further studies are needed to evaluate the pathophysiological link between cerebral atherosclerosis and FDG uptake in the spine and organs.
JOURNAL OF CLINICAL NEUROLOGY
(2021)
Review
Radiology, Nuclear Medicine & Medical Imaging
K. S. M. van der Geest, G. Treglia, A. W. J. M. Glaudemans, E. Brouwer, F. Jamar, R. H. J. A. Slart, O. Gheysens
Summary: [18F]FDG-PET/CT scanning can effectively diagnose polymyalgia rheumatica by identifying significant uptake of FDG at specific anatomic sites. The technique shows promise as an important diagnostic tool for patients with suspected PMR, but standardized interpretation criteria and procedural recommendations are necessary for its use.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Article
Oncology
Chao Lu, Kailiang Wang, Fei Meng, Yihe Wang, Yongzhi Shan, Penghu Wei, Guoguang Zhao
Summary: Patients with epileptogenic hypothalamic hamartoma exhibit reduced glucose metabolism and gray matter volume predominantly in the ipsilateral neocortex, as well as overall metabolic reduction in the cerebellum. Hypometabolism in the neocortex is more distributed ipsilaterally than contralaterally to the hamartoma. The characteristics of glucose hypometabolism differ based on seizure type and sex, suggesting potential involvement of specific brain pathways in seizure propagation in these patients.
FRONTIERS OF MEDICINE
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
E. Marchal, X. Palard-Novello, F. Lhomme, M. E. Meyer, G. Manson, A. Devillers, J. P. Marolleau, R. Houot, A. Girard
Summary: This study aimed to identify [F-18]FDG-PET biomarkers associated with prognosis and predictive of adverse events in patients treated with CAR T cells. TMTV and sDmax were found to have independent prognostic values on PFS and OS, respectively. In addition, the liver and spleen uptakes were associated with the occurrence of grade 2 to 4 CRS and ICANS.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Review
Oncology
Sungmin Woo, Anton S. Becker, Richard K. G. Do, Heiko Schoder, Hedvig Hricak, H. Alberto Vargas
Summary: FDG-PET or PET/CT had a meaningful impact on the management of patients with CUP, with approximately a third of patients having their management changed as a result, mainly due to detection of the primary site. This finding was consistent across numerous subgroups.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Immunology
Paolo Corradini, Chiara Agrati, Giovanni Apolone, Alberto Mantovani, Diana Giannarelli, Vincenzo Marasco, Veronica Bordoni, Alessandra Sacchi, Giulia Matusali, Carlo Salvarani, Pier Luigi Zinzani, Renato Mantegazza, Fabrizio Tagliavini, Maria Teresa Lupo-Stanghellini, Fabio Ciceri, Silvia Damian, Antonio Uccelli, Daniela Fenoglio, Nicola Silvestris, Fausto Baldanti, Giulia Piaggio, Gennaro Ciliberto, Aldo Morrone, Franco Locatelli, Valentina Sinno, Maria Rescigno, Massimo Costantini
Summary: This study investigated the immune response to the SARS-CoV-2 vaccine in patients with tumors and immune disorders. The results showed that immunosuppressive treatment was a risk factor for a low humoral response, while the booster dose improved both humoral and T-cell responses.
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Oncology
Vittorio Stefoni, Lisa Argnani, Matteo Carella, Beatrice Casadei, Alice Morigi, Ginevra Lolli, Alessandro Broccoli, Cinzia Pellegrini, Laura Nanni, Paolo Elia Coppola, Pier Luigi Zinzani
Summary: Achieving minimal disease status before autologous stem cell transplantation (ASCT) is crucial for Hodgkin lymphoma (HL) patients. This retrospective study evaluated the effectiveness and safety of the BEGEV regimen as a first salvage treatment prior to ASCT in HL patients. The results showed that the BEGEV regimen was able to induce complete response in a significant number of patients with limited toxicity, and did not impair peripheral blood stem cell mobilization.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Alessandro Broccoli, Lisa Argnani, Paolo Elia Coppola, Marianna Gentilini, Gianmarco Bagnato, Ginevra Lolli, Matteo Carella, Laura Nanni, Alice Morigi, Beatrice Casadei, Cinzia Pellegrini, Vittorio Stefoni, Pier Luigi Zinzani
Summary: After treatment with brentuximab vedotin, a proportion of patients who failed autologous stem cell transplantation for Hodgkin lymphoma can achieve and maintain long-term complete remission, indicating cure. The role of allogeneic transplantation in these patients is still being debated.
Article
Medicine, Research & Experimental
Sridhar Chaganti, Arie Barlev, Sophie Caillard, Sylvain Choquet, Kate Cwynarski, Anke Friedetzky, Eva Gonzalez-Barca, Natalia Sadetsky, Stefan Schneeberger, Dhanalakshmi Thirumalai, Pier L. Zinzani, Ralf U. Trappe
Summary: This study used a modified Delphi method to reach consensus among experts on the key characteristics of patients with EBV+ PTLD for whom chemotherapy may be inappropriate, providing guidance for clinicians in the treatment of this disease.
ADVANCES IN THERAPY
(2023)
Letter
Dermatology
Alessandro Pileri, Giacomo Clarizio, Corrado Zengarini, Beatrice Casadei, Elena Sabattini, Claudio Agostinelli, Pier Luigi Zinzani
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Article
Oncology
John Kuruvilla, Philippe Armand, Mehdi Hamadani, Justin Kline, Craig H. Moskowitz, David Avigan, Joshua D. Brody, Vincent Ribrag, Alex F. Herrera, Franck Morschhauser, Abraham Kanate, Pier Luigi Zinzani, Jacob Bitran, Herve Ghesquieres, Stephen J. Schuster, Mohammed Farooqui, Patricia Marinello, Nancy L. Bartlett
Summary: The study evaluated the safety and efficacy of pembrolizumab in patients with relapsed or refractory NHL. The results showed that pembrolizumab had good efficacy in PMBCL in patients who were ineligible or failed hematopoietic cell transplantation, but its efficacy in other NHL subtypes was uncertain. Hematologic toxicities were common treatment-related adverse events.
LEUKEMIA & LYMPHOMA
(2023)
Review
Radiology, Nuclear Medicine & Medical Imaging
Lucia Zanoni, Davide Bezzi, Cristina Nanni, Andrea Paccagnella, Arianna Farina, Alessandro Broccoli, Beatrice Casadei, Pier Luigi Zinzani, Stefano Fanti
Summary: Non-Hodgkin lymphomas encompass a diverse group of lymphoproliferative disorders with varying clinical courses. 18F-FDG-PET/CT is the current gold standard diagnostic imaging for staging, restaging, and treatment evaluation in lymphomas with high glucose avidity. PET-based response criteria are now uniformly applied in FDG-avid lymphomas, and this article provides updates on the management of diffuse large B-cell lymphoma, follicular lymphoma, and other histotypes, as well as the use of PET-derived factors for patient stratification and prognostication, and emerging radiomics research. Published in Semin Nucl Med 53:320-351 (c) 2022 by Elsevier Inc.
SEMINARS IN NUCLEAR MEDICINE
(2023)
Review
Oncology
Pier Luigi Zinzani, Francesca Romana Mauro, Alessandra Tedeschi, Marzia Varettoni, Francesco Zaja, Giovanni Barosi
Summary: Zanubrutinib has been approved for the treatment of various lymphoproliferative disorders, providing a significant breakthrough for patients who are resistant or relapse after recommended therapies. Due to the lack of systematic studies and comparative randomized clinical trials, the optimal use of zanubrutinib in approved indications presents challenges, especially in earlier stages of the disorders. This article presents the results of expert panel discussions aimed at identifying unmet clinical needs and proposing recommendations for the management of these needs.
HEMATOLOGICAL ONCOLOGY
(2023)
Article
Oncology
Michael L. Wang, Wojciech Jurczak, Pier Luigi Zinzani, Toby A. Eyre, Chan Y. Cheah, Chaitra S. Ujjani, Youngil Koh, Koji Izutsu, James N. Gerson, Ian Flinn, Benoit Tessoulin, Alvaro J. Alencar, Shuo Ma, David Lewis, Ewa Lech-Maranda, Joanna Rhodes, Krish Patel, Kami Maddocks, Nicole Lamanna, Yucai Wang, Constantine S. Tam, Talha Munir, Hirokazu Nagai, Francisco Hernandez-Ilizaliturri, Anita Kumar, Timothy S. Fenske, John F. Seymour, Andrew D. Zelenetz, Binoj Nair, Donald E. Tsai, Minna Balbas, Richard A. Walgren, Paolo Abada, Chunxiao Wang, Junjie Zhao, Anthony R. Mato, Nirav N. Shah
Summary: This study evaluated the safety and efficacy of Pirtobrutinib, a noncovalent BTK inhibitor, in patients with mantle-cell lymphoma who had previously received covalent BTK inhibitors. The results showed that Pirtobrutinib demonstrated durable efficacy and was well tolerated in this heavily pretreated patient population.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Clinical Neurology
Umberto Pensato, Giulia Amore, Lorenzo Muccioli, Susanna Sammali, Francesca Rondelli, Rita Rinaldi, Roberto D'Angelo, Marianna Nicodemo, Susanna Mondini, Luisa Sambati, Gian Maria Asioli, Simone Rossi, Rossella Santoro, Lucia Cretella, Susy Ferrari, Luca Spinardi, Luca Faccioli, Stefano Fanti, Andrea Paccagnella, Elisabetta Pierucci, Beatrice Casadei, Cinzia Pellegrini, Pier Luigi Zinzani, Massimiliano Bonafe, Pietro Cortelli, Francesca Bonifazi, Maria Guarino
Summary: In this study, the clinical and instrumental features, incidence, risk factors, and prognosis of neurotoxicity in lymphoma patients who received CAR T-cell therapy were investigated. The results showed that 37% of patients developed neurotoxicity, characterized by encephalopathy and language disturbances. Baseline EEG abnormalities were important predictors for ICANS development. Neurological symptoms were completely resolved in all patients except for one who developed fatal cerebral edema, and no long-term neurotoxicity was observed.
JOURNAL OF NEUROLOGY
(2023)
Article
Pharmacology & Pharmacy
Chun Liu, Pier Giorgio Cojutti, Maddalena Giannella, Marcello Roberto, Beatrice Casadei, Gianluca Cristiano, Cristina Papayannidis, Nicola Vianelli, Pier Luigi Zinzani, Pierluigi Viale, Francesca Bonifazi, Federico Pea
Summary: CAR T-cell therapy may cause cytokine release syndrome (CRS) and acute kidney injury, potentially affecting the pharmacokinetics of beta-lactam drugs. This study found that the clearance of meropenem and piperacillin did not need to be reduced in CAR T-cell patients experiencing CRS.
Article
Hematology
Livio Pagano, Pier Luigi Zinzani, Stefano Pileri, Pietro Quaglino, Branko Cuglievan, Emilio Berti, Naveen Pemmaraju, Francesco Onida, Rein Willemze, Alberto Orfao, Giovanni Barosi
Summary: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with recurrent skin nodules, aggressive clinical course, and poor prognosis. Due to its rarity, there is limited research, lack of controlled clinical trials, and absence of evidence-based guidelines for its management. This review presents recommendations and proposals by a panel of experts to address the unmet clinical needs in the management of BPDCN. The hope is that this comprehensive overview will improve the practice of BPDCN and guide future studies in the field.
Article
Oncology
Mehdi Hamadani, Morton Coleman, Ralph Boccia, Juraj Duras, Martin Hutchings, Pier Luigi Zinzani, Raul Cordoba, Mariana Bastos Oreiro, Vanessa Williams, Huiqing Liu, Michael Stouffs, Peter Langmuir, Juan-Manuel Sancho
Summary: The combination of parsaclisib with obinutuzumab and bendamustine showed promising clinical benefit in patients with relapsed or refractory follicular lymphoma, without unexpected safety events.
HEMATOLOGICAL ONCOLOGY
(2023)
Article
Oncology
Pietro Quaglino, Nicola Pimpinelli, Pier Luigi Zinzani, Marco Paulli, Stefano Pileri, Emilio Berti, Lorenzo Cerroni, Joan Guitart, Youn H. Kim, Serena Rupoli, Marco Santucci, Gabriele Simontacchi, Maarten Vermeer, Richard Hoppe, Barbara Pro, Steven H. Swerdlow, Giovanni Barosi
Summary: This article presents major unmet clinical needs in the management of primary cutaneous B-cell lymphomas (PCBCLs) and proposes recommendations and research directions to address these needs. These recommendations and research directions will help improve the diagnosis and treatment of PCBCLs.
HEMATOLOGICAL ONCOLOGY
(2023)
Letter
Oncology
Ginevra Lolli, Lisa Argnani, Guido Gini, Beatrice Casadei, Cinzia Pellegrini, Monica Tani, Vincenzo Pavone, Michele Cimminiello, Francesca Bonifazi, Pier Luigi Zinzani
HEMATOLOGICAL ONCOLOGY
(2023)